PFBT
UBX

Parkside Financial Bank & Trust’s Unity Biotechnology UBX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-800
Closed -$308 – 2815
2025
Q2 		$308 Hold
800
– – ﹤0.01% 2642
2025
Q1 		$832 Buy
+800
New +$1.45K ﹤0.01% 2178

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Parkside Financial Bank & Trust's UBX Position: Q3 2025 in Review

Parkside Financial Bank & Trust sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 800 shares — an estimated $308 sold.

Parkside Financial Bank & Trust first reported a position in UBX in Q1 2025 and held it in 2 quarters. The position peaked at $832 in Q1 2025. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Parkside Financial Bank & Trust reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 800 Unity Biotechnology shares in Q3 2025, an estimated $308.
  • Parkside Financial Bank & Trust first reported a position in Unity Biotechnology in Q1 2025 and held it in 2 quarters.
  • Parkside Financial Bank & Trust's Unity Biotechnology position peaked at $832 in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q3 2025, filed 30 Oct 2025.